4 / 8
Journal of Pediatric Care
ISSN: 2471-805X
March 26-27, 2018
Edinburgh, Scotland
Pediatrics Conference 2018
Page 14
2
nd
Edition of International Congress on
Pediatrics
Statement of the problem:
Dilated cardiomyopathy is a serious
problem in pediatric cardiology praxis. Despite the relatively
low incidence of 0.57 to 2.6 per 100000 children the mortality
rate is high. One third of patients die within the first year after
diagnosis. Up to 40% of these patients are defined as idiopathic
dilated cardiomyopathy (IDCM), characterized by ventricular
dilatation and systolic dysfunction. Researchers have reposted
that conventional medical therapy does not improve the outcome
of the disease; however recent clinical studies have suggested
bone marrow derived autologous mononuclear cells as a
promising therapy option. Pulmonary arterial hypertension (PAH)
is characterized by increased pulmonary vascular resistance
resulting in extensive heart structural changes leading to right
heart failure and death. PAH is characterized by obstruction
of small pulmonary arteries leading progressive increase in
vascular resistance. Locally implanted stemcellsmay trigger the
neovascularization process in the lung potentially leading to a
decrease of pulmonary artery pressure.
Methodology:
For treatment of IDCMwe prefer to use transcutan
intramyocardial administration of autologous bone marrow
derived mononuclear stem cells, combined with ultrasound
monitoring. In patients with PAH intrapulmonary transplantation
of stem cells was performed using: intravasal injection of the
stem cells by catheterization pulmonary arteries and directly
in the lung tissues by using standard thoracentesis technique,
performed under chest radiological control.
Conclusions:
Ten years’ experience applied wisely, the stem cell
therapy appears to be a safe and effective way for stabilization
of critically ill patients with both severe pulmonary arterial
hypertension and idiopathic dilated cardiomyopathy. This
method provides additional opportunities for symptomatic
treatment and serves as a bridge for potential heart and lung
transplantation
Recent Publications
1. Lācis A and Ērglis A (2011) Intramyocardial administration
of autologous bone marrowmononuclear cells in a critically
ill child with dilated cardiomyopathy. Cardiology in the
Young 21(1):110–112.
2. LācisA, Lubaua I, ĒrglisA, et al. (2013)Neo-revascularization
as the potential treatment for patient suffering from
pulmonary hypertension (Myth or reality?). J. Clinical
Medicine Research (CMR), 2(3):32–36.
3. Lācis A, Lubaua I, Ērglis A, et al. (2013) Management of
idiopathic dilated cardiomyopathy with intramyocardial
cell transplantation in children: A retrospective study of 7
patients. J. Clinical Medicine Research, 2(4):129–133.
4. Lācis A, Lubaua I, Ērglis A, et al. (2013) Safeguards and
pitfalls in technique used for stem cell delivery in children
suffering from idiopathic dilated cardiomyopathy. Journal of
US-China Med. Science, 10(3–4):71–75.
5. Lācis A, Lubaua I, Ērglis A, et al. (2014) Stem cell therapy
as one of temporary measures for management of heart
failure and pulmonary hypertension in children. American
Journal of Experimental and Clinical Research 1(3):38–46.
Using autologous bone marrow derived
mononuclear stem cells for stimulating
tissue regeneration and functional activity
Aris Lacis
University Children Hospital, Latvia
Aris Lacis, J Pediatr Care, Volume 4
DOI: 10.21767/2471-805X-C1-004